Home / Health / Pharmacy's Risky Injections Recalled Nationwide
Pharmacy's Risky Injections Recalled Nationwide
20 Oct
Summary
- Compounded GLP-1 injections recalled due to sterility concerns.
- Pharmacy previously warned by FDA for putting patients at risk.
- Class II recall issued, posing low risk of serious harm.
A nationwide recall has been issued for compounded tirzepatide injections produced by Apothecary Pharma LLC, a pharmacy previously warned by the Food and Drug Administration (FDA). The voluntary recall, initiated on September 24, 2026, and updated to a Class II recall on October 10, 2026, cites "lack of assurance of sterility" as the reason. This classification indicates that the medication could cause temporary or medically reversible adverse health consequences, though the risk of serious harm is considered small.
These injections are compounded versions of GLP-1 medications, meaning they are custom-formulated by specialized pharmacies rather than being name-brand, FDA-approved products. Compounding pharmacies have faced scrutiny in the past due to sanitation and sterility issues, such as a significant fungal meningitis outbreak in 2012 linked to the New England Compounding Center. Apothecary Pharma itself received an FDA warning letter in December 2025 detailing "serious deficiencies" in its sterile drug production practices.
Compounded GLP-1s have been a focus for the FDA following the removal of tirzepatide and semaglutide from the official drug shortage list in late 2024 and early 2025. Despite this, many compounding pharmacies have continued production, leading to warnings and legal challenges. The FDA and Apothecary Pharma have not issued specific guidance on handling affected vials, but customers are advised to contact their prescribers for instructions.
